Trial
NCT03352557
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Biogen
Collaborators
—
Condition
Alzheimer's Disease
Intervention
BIIB092
Why stopped
The study (NCT03352557) was terminated based on lack of efficacy following the placebo-controlled period readout.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-08